Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
5.29
-0.01 (-0.19%)
Sep 4, 2025, 4:00 PM - Market closed

Evoke Pharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
12.7910.255.182.511.620.02
Upgrade
Revenue Growth (YoY)
70.02%97.84%106.51%55.04%6929.00%-
Upgrade
Cost of Revenue
0.430.360.20.370.330.09
Upgrade
Gross Profit
12.369.894.982.141.29-0.06
Upgrade
Selling, General & Admin
17.6415.0812.239.628.856.43
Upgrade
Research & Development
0.060.020.180.30.596.55
Upgrade
Operating Expenses
17.715.112.419.929.4412.98
Upgrade
Operating Income
-5.34-5.2-7.43-7.79-8.15-13.05
Upgrade
Interest Expense
-0.5-0.5-0.5-0.5-0.5-0.11
Upgrade
Interest & Investment Income
0.460.350.140.060.010.01
Upgrade
EBT Excluding Unusual Items
-5.38-5.35-7.79-8.22-8.64-13.15
Upgrade
Other Unusual Items
----0.11-
Upgrade
Pretax Income
-5.38-5.35-7.79-8.22-8.54-13.15
Upgrade
Net Income
-5.38-5.35-7.79-8.22-8.54-13.15
Upgrade
Net Income to Common
-5.38-5.35-7.79-8.22-8.54-13.15
Upgrade
Shares Outstanding (Basic)
320000
Upgrade
Shares Outstanding (Diluted)
320000
Upgrade
Shares Change (YoY)
295.97%583.90%6.33%17.21%26.26%14.34%
Upgrade
EPS (Basic)
-2.03-2.81-27.97-31.39-38.20-74.31
Upgrade
EPS (Diluted)
-2.03-2.81-27.97-31.39-38.20-74.31
Upgrade
Gross Margin
96.63%96.52%96.10%85.23%79.72%-276.68%
Upgrade
Operating Margin
-41.73%-50.78%-143.44%-310.37%-503.79%-56678.32%
Upgrade
Profit Margin
-42.07%-52.22%-150.41%-327.83%-527.66%-57144.53%
Upgrade
EBIT
-5.34-5.2-7.43-7.79-8.15-13.05
Upgrade
EBIT Margin
-41.73%-50.78%-143.44%---
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q